產業組
Enterprise Group
我要報名產業組

(一)計畫簡介
 

  1. 為培育臺灣高階科技創新創業人才,引領臺灣高品質人才連結未來世界以建立我國創新平臺,科技部推動「博士創新之星計畫」(以下簡稱「本計畫」),選派具創新創業企圖心之高階人才赴美國、法國及以色列等高科技企業、新創公司以及知名學研機構進行專案合作研習1年。希望藉此開拓我國高階人才之能力與創新思維,並透過參與當地創新創業或相關社群活動,建立我國與海外創新資源之連結,進而於返臺後對臺灣產業或學研界有所貢獻。
     

(二)執行單位
 

  1. 本計畫由財團法人國家實驗研究院科技政策研究與資訊中心博士創新之星計畫辦公室(以下簡稱「本計畫辦公室」)執行。
     
  2. 為使甄選流程公平公正,本計畫之各階段甄選,將由本計畫辦公室邀請相關領域專家及企業代表組成「評選委員會」進行甄選。
     

(三)申請資格與甄選程序

 

本梯次徵選為【產業組】,申請資格與甄選程序如下:
 
(一)組別說明
 
  1. 與國際級企業、潛力新創公司、台灣創新創業中心(TIEC)及Taiwan Tech Arena(TTA)補助之新創公司等合作,研習學員進入國際企業研習,共同參與產業技術研發、產品設計、商業發展或新創實務工作。

  2. 藉由於海外一年期間參與尖端科技研發或新創資源連結,於研習返臺後投入我國相關產業,以帶動臺灣產業創新轉型。
     

(二)申請資格
 
  1. 國籍:申請人須有中華民國國籍。

  2. 年齡:40歲(含)以下。

  3. 學歷:

    • 具有國內外博士學位者(若具十大產業創新相關背景者優先:亞洲.矽谷、綠能科技、生醫產業、智慧機械、國防航太、新農業、循環經濟、數位國家創新經濟、文化科技、晶片設計與半導體產業)。

    • 非博士者,符合國家科技發展方向之相關經歷,並有特殊事蹟(包括但不限於科技創新競賽獲獎、傑出學術研發成果、領導公私部門研發專案及應用之經驗、從事科技新創並有具體成果等)。

  4. 英文能力證明:檢附107年12月以後之英文能力證明文件尤佳( 多益750分以上或同等級之其他官方檢定結果) 。

  5. 如申請人於本梯次徵選截止日前,仍繼續保有本計畫其他梯次未放棄之有效核定資格,則應依本計畫規定不得參與本梯次之徵選。
     

(三)申請方式
 
  1. 申請人須至計畫網站線上申請,報名系統網址http://LEAP.stpi.narl.org.tw。

  2. 本年度申請截止日期為109年11月30日,逾期不受理報名。

  3. 請依線上系統登錄格式內容,詳實完整填寫並檢附相關中英文資料,以利後續審查作業。

  4. 網路報名截止後,申請人即無法再修改已送出的報名資料。
     

(四)甄選流程
 


 

  • 報名申請
    申請人於申請時,可選填欲前往之海外企業或公司之研習志願。
     
  • 書面審查
    申請人於線上系統提交之書面申請資料,由參與徵選之海外企業進行書面審查,並視需要電話或視訊訪談。經夥伴機構內部審查後推薦之申請人,得免書面審查之程序。
     
  • 名單公告
    產業組預定於109年12月公告【書面審查】結果,並通知通過初審者培訓營活動細節及複選面試資訊。
     
  • 躍升培訓營
    通過書面審查的候選學員方獲得參與本計畫辦理之躍升培訓營資格,候選學員應全程參與躍升培訓營,於活動期間建立創新創業人脈、學習創業規劃、溝通及簡報技巧,並與企業先進及各海外企業代表交流互動,以利後續媒合程序。本梯次媒合時程依本計畫辦公室公告為主。
     
  • 核定公告
    本組實際獲核定學員人數,將經由審查會議決定。獲選學員與本計畫辦公室簽訂合約後,將由本計畫辦公室協助簽證申請事宜,前往海外研習單位參加研習計畫。上述程序如有異動,請依本計畫辦公室公告為主。
     

(四)補助方式

 

  1. 補助金額:
    本計畫將補助學員研習期間之補助生活費,補助金額以新臺幣150萬元為原則,國外研習期間少於一年者,按比例發放。

     
  2. 補助核發方式:
    國外研習期間,補助生活費將採里程碑撥款模式分二期撥付:
    • 第一期:第1至第6個月之補助生活費。雙方於簽訂合約且學員完成補助生活費請領手續後,於雙方約定之補助起始日前後30個日曆天內,將第一期補助生活費匯入學員指定之本人國內帳戶。
    • 第二期:第7至第12個月之補助生活費。學員應依本計畫辦公室規定時程內繳交期中報告(報告格式、內容,依本計畫辦公室公告為主),經本計畫辦公室審核通過後始撥付第二期補助生活費至學員指定之本人國內帳戶。
       

(五)權利義務

 

  1. 本計畫優先補助未曾受領政府公費補助出國之申請人,且曾受本計畫補助者不得再次申請。

  2. 公告入選之學員赴海外研習前須與本計畫辦公室簽署合約,若無法完成簽署或者主動放棄簽約者,視同放棄參與赴海外研習權利。且入選學員除應履行本計畫簡章之相關事項外,亦應確實遵守雙方簽署之合約。

  3. 由於入選學員赴海外研習作業受簽證作業時程影響,確切赴海外時間依據入選學員之入境簽證文件為準,至遲須於本計畫辦公室公告之時程內抵達選定之海外研習機構。

  4. 學員在海外研習期間,不得從事與研習目的無關之活動(包含原職)。若因故無法繼續參與本計畫之研習,除經本計畫辦公室書面同意者外,需依合約負返還已受領之費用及相關賠償責任。

  5. 學員於本計畫之研習期間內應於指定期間內依規定繳交期中報告及結案報告,並通過審查(報告格式、內容,依本計畫辦公室公告為主)。

  6. 獲本計畫補助之學員有返國服務之義務,凡於本國境內公私部門服務,皆視為返國服務。返國服務之年限必須與所受領補助期限相同,學員應於研習結束後五年之內返國服務。如有違反,違約學員須立即返還所受領之全額生活補助費用及研習費用。

  7. 科技部或本計畫辦公室不為結束研習之學員安排工作,學員需自行洽談覓職事宜。

  8. 其他學員權利義務以合約規範內容為準。
     


(六)其他注意事項

 

  1. 本計畫之相關資訊與公告請密切注意本計畫網站:
    http://LEAP.stpi.narl.org.tw
    聯絡窗口:博士創新之星計畫辦公室
    聯絡電話:產業組02-2737-7768
    電子信箱:LEAP@narlabs.org.tw
    聯絡地址:10636臺北市和平東路二段106號1樓

     
  2. 本計畫簡章如有未盡事宜,得由本計畫辦公室隨時修訂公布之。
LEAP 2020 3rd Batch Host Companies List
查詢
Applied Materials

Applied Materials is a world-wide largest Semiconductor and Display equipment manufacturer.

Apeximmune Therapeutics Inc

Apeximmune Therapeutics seeks to harness the power of the immune system to treat and cure cancer. We discover and pioneer innovative therapeutic antibodies against novel targets to modulate immune cell activity and elicit durable efficacy in cancer. Apeximmune’s target discovery platform combines bioinformatics with biological assays to enable identification of novel immune modulating targets. Currently, antibodies for three immuno-oncology target programs in the pre-clinical stage are being actively developed with the goal of reaching IND status within 18 months.

BioLegend Inc.

BioLegend develops world-class, cutting-edge antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA.  Our mission is to accelerate research and discovery by providing the highest quality products at an outstanding value, along with superior customer service and technical support.
Our product expertise covers a diverse set of research areas including Immunology, Neuroscience, Cancer, Stem cells, and Cell Biology. BioLegend's reagents are supported by superior customer service and a quality management system that is certified for ISO 13485:2016. Our aggressive product development program, through technology licensing, collaborations, and internal hybridoma development, produces strategic reagents for use in a variety of applications including:

Flow cytometry and mass cytometry
ELISA and ELISPOT
Immunoprecipitation and ChIP
Western blotting
Immunofluorescence microscopy
Immunohistochemistry
In vitro or in vivo functional assays.
Quantitative Multiplexing
BioLegend offers the broadest selection of fluorochrome conjugates for multi-color flow cytometry. With an experienced biochemistry team, BioLegend is well positioned to offer a wide range of custom conjugation services to meet our customers' specific needs.

Our commitment to the research community is reflected in generous sponsorships of societies and meetings world-wide, our monthly travel award for junior investigators, and excellent bulk pricing. With iPhone/iPad apps, web tools, beautifully detailed posters, and new reagents, we look forward to bringing more creative innovation to make your research legendary.

Genentech

Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. Genentech became a member of the Roche Group in March of 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech's South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech Research and Early Development operates as an independent center within Roche.

Kyocera International Inc.

Kyocera International Inc. is a subsidiary of Kyocera Corporation. Kyocera International Inc. conducts business in multiple areas (Semiconductor Components, Communication Equipment Group, Fine Ceramics Group, Optical Division, Consumer Product Division, Display Division, Automotive Components). The division which will participate in LEAP activity has been developing mmWave phased-array antenna for past 30 years. The division is actively developing RFIC, microwave package, phased-array antenna for 5G cellular and Satellite market. 

LIGHTEL TECHNOLOGIES INC.

LIGHTEL is an advanced technology company located in the Greater Seattle to service the Fiber Optics & Photonics industries worldwide. The new focus is to develop Hi-power (KW) technologies for
Fiber Laser applications to serve the Industry 4.0., IMS (Intelligent Manufacturing System) and
Autonomous Vehicles.

NVIDIA

NVIDIA’s invention of the GPU sparked the PC gaming market. The company’s pioneering work in accelerated computing—a supercharged form of computing at the intersection of computer graphics, high performance computing and AI—is reshaping trillion-dollar industries, such as transportation, healthcare and manufacturing, and fueling the growth of many others.

Omega Optics

PARTNERS AND COLLABORATORS

Omega Optics, Inc. is a leading company started in Austin, Texas in 2001. Since its initiation, Omega Optics has been actively involved in optical communications/sensing field where arrays of products have been developed from internal R&D and SBIR/STTR efforts. Technologies including portable bio-sensing, polymer based planar light wave circuit for EM-wave sensing, chemical and biological sensing , and nanophotonics for integrated photonic circuits, are core technologies. Omega Optics, with its vast experience in SBIR/STTR programs, is in a vantage position to pursue this aggressive commercialization strategy. Omega’s scientists and engineers have research project experience with partners and sponsors such as General Electric, Cray Research, Honeywell, 3M, Dell, Lightpath, Boeing, Physical Optics Corp., Novex Corp., Lambda Physik USA. The management team has a commercialization track record of raising $18 million venture capital investment SBIR phase II matching funds in 2000 from Intel venture, KLM venture which was later acquired by Finisar, a publicly traded company, in 2001.

PETCOIL, INC.

Founded in 2018, PETcoil was formed by a group of imaging scientists, engineers, and radiologists aspired to improve healthcare by creating novel medical imaging technology and bringing it to millions of patients around the globe. Our team has its roots at Stanford University, where our founders created their first-ever radiofrequency-penetrable PET insert system for simultaneous PET and MRI imaging.

Our vision is to make multi-modality medical imaging accessible to every patient. Our mission is to create affordable, high-performance molecular imaging systems to drive early and accurate diagnosis of diseases.

Pfizer Inc.

(Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines.

Taboola

Taboola helps people find relevant content online, matching them with news stories, articles, blogs, videos, apps, products and other content they’re likely to want to explore.
How do we know what they’ll like? Using machine-learning algorithms, our technology analyzes hundreds of signals to capture exactly what kind of content is most likely to engage each individual. We do that more than 450 billion times a month for more than one billion unique users.

Since we opened our doors in 2006, we have grown to become the leading discovery platform on the open web, serving a combination of the world’s best brands and the most respected global publishers.

Taboola is headquartered in New York City with local offices in Los Angeles, London, Tel Aviv, New Delhi, Bangkok, São Paulo, Beijing, Shanghai, Istanbul, Seoul, Sydney and Tokyo.

Thermo Fisher Scientific

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry.

Tubis Technology Inc.

Tubis Technology Inc. has been developing mmWave phased-array antenna for 5G cellular and Satellite market for the past 6 years. The area of focus and expertise is Semiconductor Design – Advanced CMOS and GaAs, Packaging Technology – antenna in package and silicon in package, RF systems technology – RF IC design, phased-array technology, beam forming

Wearifi Inc.

By designing wearable devices in new ways, Wearifi is a technology company seeking to create epidermal electronics with all of the performance of the current state of the art at a fraction of the size. Our mission is to devise the next generation of electronic solutions – integrated, invisible when you want them to be, and battery-free – to personal healthcare that promote positive feedback between cognitive science and precision medicine.
Wearifi has partnered with multiple Fortune 500 companies, the Department of Health and Human Services, and leading research hospitals to drive personalized healthcare management with wearable electronic gadgets. The core technology represents not only the outcome of research efforts from Querrey Simpson Institute for Bioelectronics at Northwestern University but continuous interactions with the research/clinical teams to develop engineering solutions that are capable of non-invasively skin health monitoring, motion envelope visualization, haptic feedback for VR/AR and prosthetic applications, in-real time. At Wearifi, you’ll have an opportunity to work in a collaborative environment that leads to academic publications and technology innovations, so together we can engineer the future of smart healthcare.
 

more